New drug combo targets rare, Tough-to-Treat cancer caused by prior therapy
NCT ID NCT05379166
Summary
This study is testing whether two drugs, venetoclax and azacitidine, work better together to treat a specific type of bone marrow cancer called therapy-related myelodysplastic syndrome (t-MDS). This cancer can develop after a person has received chemotherapy or radiation for a previous cancer. The main goal is to see if this combination can put the disease into complete remission. The trial is for adults with previously untreated, higher-risk t-MDS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.